Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q2 FY262026-06-30 | Q1 FY262026-03-31 | Q4 FY252025-12-31 | Q3 FY252025-09-30 | Q2 FY252025-06-30 | Q1 FY252025-03-31 | Q4 FY242024-12-31 | Q3 FY242024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.22B | $1.14B | $1.09B | $1.11B | $1.11B | $998.43M | $954.29M | $975.54M |
| Cost of revenue | $437.50M | $418.08M | $432.47M | $421.89M | $414.73M | $375.05M | $383.63M | $379.51M |
| Gross profit | $779.09M | $722.74M | $658.11M | $683.35M | $694.73M | $623.38M | $570.66M | $596.04M |
| Gross margin | 64.0% | 63.4% | 60.3% | 61.8% | 62.6% | 62.4% | 59.8% | 61.1% |
| Research and development | $65.43M | $65.79M | $66.83M | $63.42M | $61.90M | $59.06M | $57.73M | $53.98M |
| Selling, general and administrative | $288.09M | $294.37M | $275.68M | $265.09M | $259.79M | $247.78M | $251.25M | $238.17M |
| Operating expenses | $353.52M | $360.15M | $342.51M | $328.51M | $321.69M | $306.85M | $308.97M | $292.15M |
| Operating income | $425.57M | $362.59M | $315.61M | $354.85M | $373.05M | $316.53M | $261.69M | $303.89M |
| Operating margin | 35.0% | 31.8% | 28.9% | 32.1% | 33.6% | 31.7% | 27.4% | 31.2% |
| EBITDA | $466.62M | $400.27M | $354.33M | $391.47M | $408.82M | $350.60M | $295.39M | $338.03M |
| Interest income | $606.00K | $597.00K | $587.00K | $580.00K | $627.00K | $1.22M | $2.20M | $2.71M |
| Interest expense | −$10.18M | −$7.74M | −$9.21M | −$10.66M | −$11.32M | −$7.67M | −$7.50M | −$7.70M |
| Income before taxes | $417.22M | $355.44M | $306.98M | $344.77M | $362.35M | $310.08M | $256.39M | $298.91M |
| Income taxes | $78.81M | $77.00M | $58.79M | $70.16M | $68.36M | $67.41M | $40.24M | $66.07M |
| Net income | $338.41M | $278.45M | $248.19M | $274.61M | $293.99M | $242.68M | $216.15M | $232.84M |
| Net margin | 27.8% | 24.4% | 22.8% | 24.8% | 26.5% | 24.3% | 22.7% | 23.9% |
| EPS, basic | $4.29 | $3.50 | $3.11 | $3.43 | $3.66 | $2.98 | $2.64 | $2.83 |
| EPS, diluted | $4.27 | $3.47 | $3.08 | $3.40 | $3.63 | $2.96 | $2.62 | $2.80 |
| Diluted shares | 79.31M | 80.16M | 80.51M | 80.68M | 80.99M | 81.92M | 82.58M | 83.06M |
Figures describe IDEXX Laboratories shares, not any token. As of Aug 4, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.